Diabetic hemodialysis. Type 2 diabetes mellitus with diabetic chronic kidney disease
Conditions
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Diabetic patients undergoing hemodialysis who have been on dialysis for at least 3 months Two or three dialysis sessions a week The duration of each session dialysis is 4 hours Patients who desire to enter the study Patients over 18 years of age
Exclusion criteria
Exclusion criteria: History of acute gastrointestinal disease History of Thyroid disorders History of gallstones Consumption of fish oil supplement Consumption steroid and non-steroidal anti-inflammatory drugs Consumption of Levothyroxine Consumption of Warfarin Consumption of antioxidant supplements History of ginger allergy Smoking
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cholestrol. Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of Cholesterol by enzymatic method.;Triglyceride. Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of Triglycerides by enzymatic method.;Low density lipoprotein (LDL). Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: LDL measurement by enzymatic method.;High density lipoprotein (HDL). Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of HDL by enzymatic method.;Anthropometric measure. Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Height measurement with a meter and weight measurement with a scale.;Level of high sensivity C-reactive protein (hs-CRP) inflammatory factor. Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of hs-CRP by immuno-turbidimetric method.;Level of Interleukine-6 (IL-6) inflammatory factor. Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of IL6 with ELISA kit.;Platelet lymphocyte ratio (PLR). Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of PLR by CBC test.;Neutrophil lymphocyte ratio (NLR). Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of NLR by CBC test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Intake calories and macronutrients. Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Recall and record food Questionnaires. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParisa veisi
Tabriz University of Medical Sciences
Outcome results
None listed